Hot Topics in Thromboembolic Disease

This curriculum is intended to build confidence in applying strategies for the prevention and management of thromboembolic disease and to ensure best practices across all clinical indications and care settings. Adherence concerns and patient uncertainty can be alleviated by ensuring that patients are educated by their provider on the differences between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin, why monitoring is not required for NOACs, and the importance of adherence to prescribed therapy.

Anticoagulation and Adherence: Improving Outcomes for Patients on NOACs CME
Drs Spyropoulos and Khorana discuss effective strategies to improve adherence to long-term therapy with NOACs.
September 23, 2015
Challenging Cases in Thromboembolic Disease: Practice Your Skills CME
Explore clinical evidence and updated guidelines on acute and long-term management of VTE.
September 17, 2015
Current Controversies in Venous Thromboembolism Treatment: Agents, Regimens, and Reversal CME
Dr Streiff and an expert panel discuss VTE management with NOACs and conventional therapy.
June 26, 2015
NOACs for VTE Prophylaxis in Orthopedic Surgery: Balancing Safety and Efficacy CME
Drs Streiff and Mont discuss the use of NOACs for venous thromboembolism prevention in patients undergoing major orthopedic surgery.
June 26, 2015

Is Your Patient on a NOAC Undergoing a Procedure? Practical Strategies and Considerations CME
Tune in to see how Dr Weitz and Dr Patel manage their patients on NOACs when they require an elective procedure.
January 15, 2016
NOACs in the ER: Bleeding Management and Reversal Strategies CME
In this episode Drs Weitz and Patel will offer strategies for managing bleeding episodes in patients on NOACs in an emergency setting.
December 18, 2015
Cancer and Pulmonary Embolism: Do We Have New Treatment Options? CME
In this episode Drs Streiff and Dr Weitz discuss how NOACs vs conventional VTE treatments compare when managing VTE in patients with cancer.
November 23, 2015
Outpatient Management of DVT/PE: NOACs Revisited CME
Tune in to our first episode with Dr Michael Streiff and Dr Jeffrey Weitz to learn about the clinical value of NOACs vs conventional VTE treatments in the outpatient setting.
October 29, 2015

Steering Committee Chair

Michael B. Streiff, MD
Associate Professor,
Johns Hopkins Medicine,
Baltimore, Maryland

Steering Committee Members

Jack E. Ansell, MD
Professor of Medicine,
Hofstra North Shore/LIJ
School of Medicine,
Hempstead, New York
Elaine M. Hylek, MD, MPH
Professor of Medicine
Boston University
School of Medicine,
Boston, Massachusetts
Alok A. Khorana, MD
Professor of Medicine,
Cleveland Clinic Lerner
College of Medicine,
Case Western Reserve University;
Sondra and Stephen Hardis
Chair in Oncology Research,
Vice Chair (Clinical Services);
Director, GI Malignancies Program,
Taussig Cancer Institute,
Cleveland Clinic,
Cleveland, Ohio

Manesh R. Patel, MD
Associate Professor of Medicine,
Duke University School of Medicine,
Durham, North Carolina
Alex C. Spyropoulos, MD
Professor of Medicine,
Hofstra North Shore-LIJ
School of Medicine,
Hempstead, New York

Supported by an independent educational
grant from

Janssen Pharmaceuticals

Developed through a collaboration between Medscape and

Steering Committee

Michael B. Streiff, MD

Participation by Dr Streiff as an advisor does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Michael B. Streiff, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Portola Pharmaceuticals, Inc.

Served as a paid member of committee, panel, or board for BiO2 Medical Inc.

Jack E. Ansell, MD

Jack E. Ansell, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alere; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Instrumentation Laboratory; Perosphere; Pfizer Inc; Roche
Owns equity in: Perosphere

Elaine M. Hylek, MD, MPH

Elaine M. Hylek, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Medtronic, Inc.; Pfizer Inc
Received honoraria from: Bayer HealthCare Pharmceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company

Alok A. Khorana, MD

Alok A. Khorana, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AngioDynamics, Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Halozyme Therapeutics; Janssen Pharmaceuticals; Leo Pharma Inc.; Pfizer Inc; Roche
Served as a paid member of committee, panel, or board for Janssen Pharmaceuticals; Leo Pharma Inc.

Manesh R. Patel, MD

Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Genzyme Corporation; Merck & Co., Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; MAQUET, Inc.

Alex C. Spyropoulos, MD

Alex C. Spyropoulos, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer Healthcare, Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Pfizer Inc
Received grants for clinical research from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals

	How does your institution utilize scored venous thromboembolism (VTE) risk assessment models to manage thromboprophylaxis in hospitalized medical patients?
		It never does
		It does but is an optional feature
		It is part of the electronic health record (EHR)
		Our system uses group-specific VTE prophylaxis strategies